{"mainPropery":{"diseaseId":10365,"diseaseName":"Sepiapterin reductase deficiency","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10365/sepiapterin-reductase-deficiency","synonyms":["SPR deficiency","DYT/PARK-SPR","Dopa-responsive dystonia due to sepiapterin reductase deficiency","SR-deficient DRD"],"synonyms-with-source":[{"name":"SPR deficiency"},{"name":"DYT/PARK-SPR","source":"Pubmed"},{"name":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","source":"Orphanet"},{"name":"SR-deficient DRD","source":"GeneReviews"}],"identifiers":[{"identifierType":"OMIM","identifierId":"612716"},{"identifierType":"ORPHANET","identifierId":"70594"},{"identifierType":"UMLS","identifierId":"C0268468"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":15,"diseaseTypeName":"Musculoskeletal Diseases"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":138,"resourceName":"Metabolic Support UK","abbreviation":"","address1":"5 Hilliards Court","address2":"Sandpiper Way","address3":"Chester Business Park","address4":"","address5":"","city":"Chester","state":"","zip":"CH4 9QP","country":"United Kingdom","phone":"0845 241 2173","tty":"","tollFree":"0800 652 3181 ","fax":"","email":"https://www.metabolicsupportuk.org/contact-us","url":"https://www.metabolicsupportuk.org","freeText":""},{"resourceID":272,"resourceName":"Pediatric Neurotransmitter Disease Association","address1":"28 Prescott Place","address2":"","address3":"","address4":"","address5":"","city":"Old Bethpage","state":"NY","zip":"11804","country":"United States","phone":"603-733-8409","tty":"","tollFree":"","fax":"","email":"pnd@pndassociation.org","url":"http://www.pndassoc.org/"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/612716' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=%28%22sepiapterin+reductase%22%5BSubstance+Name%5D+OR+%22sepiapterin+reductase%22%5BAll+Fields%5D%29+AND+%28%22deficiency%22%5BSubheading%5D+OR+%22deficiency%22%5BAll+Fields%5D%29' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Sepiapterin reductase deficiency. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Sepiapterin reductase deficiency. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1221,"resourceId":1888,"resourceName":"Sepiapterin reductase deficiency","descriptionText":"B. G. R. Neville, Â R. Parascandalo, R. Farrugia and A. Felice, <a href='http://brain.oxfordjournals.org/cgi/reprint/128/10/2291 ' target='_blank'>Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder</a>, Brain (2005) 128(10):2291-2296.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":1397,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"The U.S. National Institutes of Health, through the National Library of Medicine, developed ClinicalTrials.gov to provide patients, family members, and members of the public with current information on clinical research studies. There is a study titled <a href='https://clinicaltrials.gov/ct2/show/NCT02769949' target='_blank'>Pediatric Patients With Metabolic or Other Genetic Disorders</a>&nbsp;which may be of interest to you.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0268468' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK304122/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ResearchTrials_Search.php?lng=EN&type_list=researchtrials_search_simple_shd&data_id=10965&Disease(s)%20concerned=Motor-and-cognitive-disorder-due-to-sepiapterin-reductase-deficiency&search=ResearchTrials_Search_Simple&ChdId=10965&ResearchTrials_ResearchTrials_Search_diseaseGroup=sepiapterin&ResearchTrials_ResearchTrials_Search_diseaseType=Pat&ResearchTrials_ResearchTrials_Search_country=NN&ResearchTrials_ResearchTrials_Search_GeographicType=null' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1541,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search.php?lng=EN&type_list=clinicalLabs_search_simple_shd&data_id=10965&Disease(s)%20concerned=Motor-and-cognitive-disorder-due-to-sepiapterin-reductase-deficiency&search=ClinicalLabs_Search_Simple&ChdId=10965&ClinicalLabs_ClinicalLabs_Search_diseaseGroup=sepiapterin&ClinicalLabs_ClinicalLabs_Search_diseaseType=Pat&ClinicalLabs_ClinicalLabs_Search_country=NN&ClinicalLabs_ClinicalLabs_Search_GeographicType=null&ClinicalLabs_ClinicalLabs_Search_ClinicalLabsList_Sort=QoS' target='_blank'>Orphanet</a> lists international laboratories offering diagnostic testing for this condition.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:612716' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":1301,"questionText":"What is sepiapterin reductase deficiency?","answerText":"<strong>Sepiapterin reductase deficiency</strong>&nbsp;is&nbsp;a neurometabolic disorder characterized by a pattern of involuntary sustained muscle contractions known as <a href=\"https://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>. Other common features include axial <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm\" target=\"_blank\">hypotonia</a> , <a href=\"http://www.merriam-webster.com/medical/oculogyric%20crisis\" target=\"_blank\">oculogyric crises</a>,  and delays in motor and cognitive development. The condition is caused by mutations in the <em><a href=\"https://ghr.nlm.nih.gov/gene/SPR\" target=\"_blank\">SPR</a></em> gene. It is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>&nbsp;fashion.[11292][11293]&nbsp;Treatment with levodopa (L-dopa) in combination with carbidopa has shown much success&nbsp;causing drastic improvements in motor functioning.[11293][11294]","dateModified":"2016-04-19T00:00:00"},"basicQuestions":[{"questionId":1305,"questionText":"What are the symptoms of sepiapterin reductase deficiency?","answerText":"The signs and symptoms of sepiapterin reductase deficiency vary from significant motor and cognitive delays to only minor findings. The condition often starts with nonspecific features in infancy, including <a href=\"http://www.parentcenterhub.org/repository/ei-overview/#delay\" target=\"_blank\">developmental delay</a>&nbsp;and <a href=\"http://www.ninds.nih.gov/disorders/hypotonia/hypotonia.htm\" target=\"_blank\">hypotonia</a>, with other features developing over time.&nbsp;The majority of affected individuals have the following features, which show diurnal fluctuation and sleep benefit (being worse at night and better in the morning after sleeping):[11292][11293][11294]<br />\r\n<ul>\r\n    <li>motor and speech delay</li>\r\n    <li>hypotonia affecting the trunk and limbs (axial hypotonia)</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>&nbsp;(unusual body posturing or twisting movements&nbsp;that are caused by&nbsp;uncontrolled muscle contractions)</li>\r\n    <li>weakness</li>\r\n    <li>oculogyric crises (abnormal rotation of the eyeballs; extreme irritability and agitation; and pain, muscle spasms, and uncontrolled movements, especially of the head and neck)&nbsp;</li>\r\n</ul>\r\nOther common features include:[11292][11293][11294]<br />\r\n<ul>\r\n    <li>parkinsonian signs (tremor, bradykinesia (slowness of mevement), masked facies, rigidity)</li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/microcephaly/microcephaly.htm\" target=\"_blank\">microcephaly</a> </li>\r\n    <li>seizures</li>\r\n    <li>limb <a href=\"http://www.ninds.nih.gov/disorders/hypertonia/hypertonia.htm\" target=\"_blank\">hypertonia</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/007470.htm\" target=\"_blank\">dysarthria</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001431.htm\" target=\"_blank\">hyperreflexia</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm\" target=\"_blank\">intellectual disability</a></li>\r\n    <li>psychiatric and/or behavioral abnormalities (anxiety, irritability)</li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/dysautonomia/dysautonomia.htm\" target=\"_blank\">autonomic dysfunction</a></li>\r\n    <li>sleep disturbances (<a href=\"http://www.ninds.nih.gov/disorders/hypersomnia/hypersomnia.htm\" target=\"_blank\">hypersomnia</a>, difficulty initiating or maintaining sleep, and drowsiness)</li>\r\n</ul>","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1304,"questionText":"What causes sepiapterin reductase deficiency?","answerText":"Sepiapterin reductase deficiency is caused by <a href=\"http://www.genome.gov/glossary.cfm?key=mutation\" target=\"_blank\">mutations</a> in the <em><a href=\"https://ghr.nlm.nih.gov/gene/SPR\" target=\"_blank\">SPR</a></em> gene. This gene provides instructions for making the sepiapterin reductase enzyme, which is involved in the productions of a molecule called tetrahydrobiopterin (also known as BH4).[11292][11293][11294] Sepiapterin reductase is specifically responsible for the last step in the production of tetrahydrobiopterin. Tetrahydrobiopterin helps process several building blocks of proteins (<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002222.htm\" target=\"_blank\">amino acids</a>), and is involved in the production of chemicals called <a href=\"http://www.dictionary.com/browse/neurotransmitter\" target=\"_blank\">neurotransmitters</a>, which transmit signals between nerve cells and the brain.[11292]<br />\r\n<br />\r\nSPR gene mutations disrupt the production of sepiapterin reductase. This leads to a reduction or absence of&nbsp;tetrahydrobiopterin. Without tetrahydrobiopterin, the brain cannot produce dopamine and serotonin, leading to the symptoms of sepiapterin reductase deficiency.[11292]","dateModified":"2016-04-19T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1307,"questionText":"How is sepiapterin reductase deficiency diagnosed?","answerText":"Sepiapterin reductase deficiency may be considered in children with characteristic clinical findings, including <a href=\"http://www.parentcenterhub.org/repository/ei-overview/#delay\" target=\"_blank\">developmental delays</a>&nbsp;with <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm\" target=\"_blank\">hypotonia</a>, unexplained <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000716.htm\" target=\"_blank\">cerebral palsy</a>, especially when <a href=\"https://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a> is present, and an L-dopa responsive motor disorder.[11294] <br />\r\n<br />\r\nDiagnosis is based on characteristic abnormalities of&nbsp;<a href=\"http://www.dictionary.com/browse/neurotransmitter\" target=\"_blank\">neurotransmitters</a>&nbsp;and pterins in the&nbsp;<a href=\"http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&amp;va=cerebrospinal%20fluid\" target=\"_blank\">cerebrospinal fluid</a>.[11294][11293][787] More specifically,&nbsp;cerebrospinal fluid findings include low levels of 5-hydroxyindolacetic acid (5-HIAA) and homovanillic acid (HVA); slightly increased levels of neopterin; and elevated total biopterin and dihydrobiopterin (BH2). Sepiapterin reductase activity in fibroblasts is usually reduced or absent. Molecular genetic testing can identify mutations in the SPR gene, confirming the diagnosis.[11294][11293] Testing can be done using single-gene testing or a multi-gene panel.[11294]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1308,"questionText":"How might sepiapterin reductase deficiency be treated?","answerText":"Treatment of sepiapterin reductase deficiency may involve levodopa (L-dopa), carbidopa and 5-hydroxytryptophan.[11293][11294] General information on levodopa and carbidopa can be found on the MedlinePlus Web site by <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601068.html\" target=\"_blank\">clicking here</a>.&nbsp;&nbsp;<br />\r\n<br />\r\nTreatment should be started as soon as possible in order to avoid irreversible neurological damage and continued for life.[11293]&nbsp;The amounts of L-dopa administered to people with sepiapterin reductase deficiency vary, but, in general, tends to be between 0.1 and 16 mg/kg/day. 5-hydroxytryptophan doses tend to be between 0.14 to 6 mg/kg/day.[11293][11294] Combination therapy is introduced slowly and increased by  over the course of days or weeks until the final target concentration is reached. People receiving this treatment regimen require careful monitoring because increasing the dose too quickly can cause side-effects. Patients receiving treatment may be monitored with routine evaluations by a pediatric neurologist, video documentation, and follow-up testing looking at cerebral spinal fluid (CSF) metabolite concentrations. Samples of CSF are&nbsp;obtained by <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003428.htm\" target=\"_blank\">lumbar puncture</a>.[787] <br />\r\n<br />\r\nIf L-dopa and 5-hydroxytryptophan in combination with carbidopa are not well tolerated or don't achieve the desired results, other medications may be considered. These include monoamine oxidase inhibitors, serotonin reuptake inhibitors, melatonin, dopamine agonists, anticholinergics, and methylphenidate. While these medications address the motor abnormalities of the condition, cognitive delays commonly remain.[11294]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1306,"questionText":"Is sepiapterin reductase deficiency genetic?","answerText":"Yes.&nbsp;It&nbsp;is thought to be inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>  pattern.[11292][11293][11294] This means that to be affected, a person must have a&nbsp;<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>&nbsp;in both copies of the responsible&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a>&nbsp;in each cell. Affected people inherit one mutated gene from each parent, who is referred to as a&nbsp;<a href=\"http://www.genome.gov/glossary/?id=23\" target=\"_blank\">carrier</a>. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:&nbsp;<br />\r\n<ul>\r\n    <li>25% (1 in 4) chance to be affected</li>\r\n    <li>50% (1 in 2) chance to be an unaffected carrier like each parent</li>\r\n    <li>25% (1 in 4) chance to be unaffected <em>and</em> not be a carrier</li>\r\n</ul>\r\n&nbsp;","dateModified":"2016-04-19T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1310,"questionText":"What is the long-term outlook (prognosis) for people with sepiapterin reductase deficiency?","answerText":"Prognosis depends on disease severity and how quickly treatment can be started.[11293] Children with this condition who are treated with levodopa medications tend to show great improvement in motor skills. The effectiveness of levodopa therapy on cognitive outcome varies. Children often have moderate-to-significant learning disabilities, especially if treatment is delayed.[11293][787]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":9817,"relatedDiseaseName":"Dopa-responsive dystonia","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":22706,"abbreviatedInquiry":"My child has been diagnosed with sepiapterin reductase deficiency. What is this condition? How is it treated?&nbsp;How long does it take for the effects of treatment with levodopa to become noticeable?","caseQuestions":[{"questionId":1301,"questionText":"What is sepiapterin reductase deficiency?","answerText":"<strong>Sepiapterin reductase deficiency</strong>&nbsp;is&nbsp;a neurometabolic disorder characterized by a pattern of involuntary sustained muscle contractions known as <a href=\"https://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>. Other common features include axial <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm\" target=\"_blank\">hypotonia</a> , <a href=\"http://www.merriam-webster.com/medical/oculogyric%20crisis\" target=\"_blank\">oculogyric crises</a>,  and delays in motor and cognitive development. The condition is caused by mutations in the <em><a href=\"https://ghr.nlm.nih.gov/gene/SPR\" target=\"_blank\">SPR</a></em> gene. It is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>&nbsp;fashion.[11292][11293]&nbsp;Treatment with levodopa (L-dopa) in combination with carbidopa has shown much success&nbsp;causing drastic improvements in motor functioning.[11293][11294]","dateModified":"2016-04-19T00:00:00","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1302,"questionText":"What are inborn errors of metabolism?","answerText":"Our bodies get the energy they need from food through metabolism, the chemical reactions in the body's cells that convert the fuel from food into the energy needed to do everything from moving to thinking to growing. Specific <a href=\"http://www.genome.gov/glossary.cfm?key=protein\" target=\"_blank\">proteins</a> in the body control the chemical reactions of metabolism, and each chemical reaction is coordinated with other body functions.[786] <br />\r\n<br />\r\nIn a broad sense, a metabolic disorder is any disease that is caused by an abnormal chemical reaction in the body's <a href=\"http://www.genome.gov/glossary.cfm?key=cell\" target=\"_blank\">cells</a>. Most disorders of metabolism involve either abnormal levels of <a href=\"http://www.genome.gov/glossary.cfm?key=enzyme\" target=\"_blank\">enzymes</a> or <a href=\"http://www.nlm.nih.gov/medlineplus/hormones.html\" target=\"_blank\">hormones</a> or problems with the functioning of those enzymes or hormones. When the metabolism of body chemicals is blocked or defective, it can cause a buildup of toxic substances in the body or a deficiency of substances needed for normal body function, either of which can lead to serious symptoms.[786] Some metabolic diseases are inherited and these conditions are called inborn errors of metabolism.[786]","dateModified":"2016-07-13T00:00:00","references":[{"referenceId":786,"authors":"","articleTitle":"A body basics article: Metabolism","bookWebsiteJournalTitle":"Kids Health","date":"June 2015","volume":"","pages":"","url":"http://kidshealth.org/parent/general/body_basics/metabolism.html","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1304,"questionText":"What causes sepiapterin reductase deficiency?","answerText":"Sepiapterin reductase deficiency is caused by <a href=\"http://www.genome.gov/glossary.cfm?key=mutation\" target=\"_blank\">mutations</a> in the <em><a href=\"https://ghr.nlm.nih.gov/gene/SPR\" target=\"_blank\">SPR</a></em> gene. This gene provides instructions for making the sepiapterin reductase enzyme, which is involved in the productions of a molecule called tetrahydrobiopterin (also known as BH4).[11292][11293][11294] Sepiapterin reductase is specifically responsible for the last step in the production of tetrahydrobiopterin. Tetrahydrobiopterin helps process several building blocks of proteins (<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002222.htm\" target=\"_blank\">amino acids</a>), and is involved in the production of chemicals called <a href=\"http://www.dictionary.com/browse/neurotransmitter\" target=\"_blank\">neurotransmitters</a>, which transmit signals between nerve cells and the brain.[11292]<br />\r\n<br />\r\nSPR gene mutations disrupt the production of sepiapterin reductase. This leads to a reduction or absence of&nbsp;tetrahydrobiopterin. Without tetrahydrobiopterin, the brain cannot produce dopamine and serotonin, leading to the symptoms of sepiapterin reductase deficiency.[11292]","dateModified":"2016-04-19T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1305,"questionText":"What are the symptoms of sepiapterin reductase deficiency?","answerText":"The signs and symptoms of sepiapterin reductase deficiency vary from significant motor and cognitive delays to only minor findings. The condition often starts with nonspecific features in infancy, including <a href=\"http://www.parentcenterhub.org/repository/ei-overview/#delay\" target=\"_blank\">developmental delay</a>&nbsp;and <a href=\"http://www.ninds.nih.gov/disorders/hypotonia/hypotonia.htm\" target=\"_blank\">hypotonia</a>, with other features developing over time.&nbsp;The majority of affected individuals have the following features, which show diurnal fluctuation and sleep benefit (being worse at night and better in the morning after sleeping):[11292][11293][11294]<br />\r\n<ul>\r\n    <li>motor and speech delay</li>\r\n    <li>hypotonia affecting the trunk and limbs (axial hypotonia)</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>&nbsp;(unusual body posturing or twisting movements&nbsp;that are caused by&nbsp;uncontrolled muscle contractions)</li>\r\n    <li>weakness</li>\r\n    <li>oculogyric crises (abnormal rotation of the eyeballs; extreme irritability and agitation; and pain, muscle spasms, and uncontrolled movements, especially of the head and neck)&nbsp;</li>\r\n</ul>\r\nOther common features include:[11292][11293][11294]<br />\r\n<ul>\r\n    <li>parkinsonian signs (tremor, bradykinesia (slowness of mevement), masked facies, rigidity)</li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/microcephaly/microcephaly.htm\" target=\"_blank\">microcephaly</a> </li>\r\n    <li>seizures</li>\r\n    <li>limb <a href=\"http://www.ninds.nih.gov/disorders/hypertonia/hypertonia.htm\" target=\"_blank\">hypertonia</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/007470.htm\" target=\"_blank\">dysarthria</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001431.htm\" target=\"_blank\">hyperreflexia</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm\" target=\"_blank\">intellectual disability</a></li>\r\n    <li>psychiatric and/or behavioral abnormalities (anxiety, irritability)</li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/dysautonomia/dysautonomia.htm\" target=\"_blank\">autonomic dysfunction</a></li>\r\n    <li>sleep disturbances (<a href=\"http://www.ninds.nih.gov/disorders/hypersomnia/hypersomnia.htm\" target=\"_blank\">hypersomnia</a>, difficulty initiating or maintaining sleep, and drowsiness)</li>\r\n</ul>","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1306,"questionText":"Is sepiapterin reductase deficiency genetic?","answerText":"Yes.&nbsp;It&nbsp;is thought to be inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>  pattern.[11292][11293][11294] This means that to be affected, a person must have a&nbsp;<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>&nbsp;in both copies of the responsible&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a>&nbsp;in each cell. Affected people inherit one mutated gene from each parent, who is referred to as a&nbsp;<a href=\"http://www.genome.gov/glossary/?id=23\" target=\"_blank\">carrier</a>. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:&nbsp;<br />\r\n<ul>\r\n    <li>25% (1 in 4) chance to be affected</li>\r\n    <li>50% (1 in 2) chance to be an unaffected carrier like each parent</li>\r\n    <li>25% (1 in 4) chance to be unaffected <em>and</em> not be a carrier</li>\r\n</ul>\r\n&nbsp;","dateModified":"2016-04-19T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":11292,"authors":"","articleTitle":"Sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"June 2011","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/sepiapterin-reductase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":685,"questionText":"What is autosomal recessive inheritance?","answerText":"<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">Autosomal recessive</a> inheritance&nbsp;refers to the inheritance pattern in which two <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=\"_blank\">mutated</a> copies of the <a href=\"http://ghr.nlm.nih.gov/handbook/basics/gene\" target=\"_blank\">gene</a> that causes a disorder&nbsp;are present in each <a href=\"http://www.genome.gov/glossary.cfm?key=cell\" target=\"_blank\">cell</a>. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as <a href=\"http://www.genome.gov/glossary.cfm?key=carrier\" target=\"_blank\">carriers</a>). Autosomal recessive disorders are typically not seen in every generation of an affected family. When two people who are carriers of an autosomal recessive condition have a child, there is a 25% (1 in 4) chance that the child will be affected.[453]","dateModified":"2015-12-28T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":453,"authors":"","articleTitle":"What are the different ways in which a genetic condition can be inherited?","bookWebsiteJournalTitle":"Genetics Home Reference Web site","date":"January 25, 2016","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/handbook/inheritance/inheritancepatterns","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1307,"questionText":"How is sepiapterin reductase deficiency diagnosed?","answerText":"Sepiapterin reductase deficiency may be considered in children with characteristic clinical findings, including <a href=\"http://www.parentcenterhub.org/repository/ei-overview/#delay\" target=\"_blank\">developmental delays</a>&nbsp;with <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm\" target=\"_blank\">hypotonia</a>, unexplained <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000716.htm\" target=\"_blank\">cerebral palsy</a>, especially when <a href=\"https://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a> is present, and an L-dopa responsive motor disorder.[11294] <br />\r\n<br />\r\nDiagnosis is based on characteristic abnormalities of&nbsp;<a href=\"http://www.dictionary.com/browse/neurotransmitter\" target=\"_blank\">neurotransmitters</a>&nbsp;and pterins in the&nbsp;<a href=\"http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&amp;va=cerebrospinal%20fluid\" target=\"_blank\">cerebrospinal fluid</a>.[11294][11293][787] More specifically,&nbsp;cerebrospinal fluid findings include low levels of 5-hydroxyindolacetic acid (5-HIAA) and homovanillic acid (HVA); slightly increased levels of neopterin; and elevated total biopterin and dihydrobiopterin (BH2). Sepiapterin reductase activity in fibroblasts is usually reduced or absent. Molecular genetic testing can identify mutations in the SPR gene, confirming the diagnosis.[11294][11293] Testing can be done using single-gene testing or a multi-gene panel.[11294]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1308,"questionText":"How might sepiapterin reductase deficiency be treated?","answerText":"Treatment of sepiapterin reductase deficiency may involve levodopa (L-dopa), carbidopa and 5-hydroxytryptophan.[11293][11294] General information on levodopa and carbidopa can be found on the MedlinePlus Web site by <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601068.html\" target=\"_blank\">clicking here</a>.&nbsp;&nbsp;<br />\r\n<br />\r\nTreatment should be started as soon as possible in order to avoid irreversible neurological damage and continued for life.[11293]&nbsp;The amounts of L-dopa administered to people with sepiapterin reductase deficiency vary, but, in general, tends to be between 0.1 and 16 mg/kg/day. 5-hydroxytryptophan doses tend to be between 0.14 to 6 mg/kg/day.[11293][11294] Combination therapy is introduced slowly and increased by  over the course of days or weeks until the final target concentration is reached. People receiving this treatment regimen require careful monitoring because increasing the dose too quickly can cause side-effects. Patients receiving treatment may be monitored with routine evaluations by a pediatric neurologist, video documentation, and follow-up testing looking at cerebral spinal fluid (CSF) metabolite concentrations. Samples of CSF are&nbsp;obtained by <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003428.htm\" target=\"_blank\">lumbar puncture</a>.[787] <br />\r\n<br />\r\nIf L-dopa and 5-hydroxytryptophan in combination with carbidopa are not well tolerated or don't achieve the desired results, other medications may be considered. These include monoamine oxidase inhibitors, serotonin reuptake inhibitors, melatonin, dopamine agonists, anticholinergics, and methylphenidate. While these medications address the motor abnormalities of the condition, cognitive delays commonly remain.[11294]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11294,"authors":"Friedman J","articleTitle":"Sepiapterin Reductase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 1, 2015","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK304122/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1309,"questionText":"How long does it take for levodopa medications to become effective?","answerText":"Levodopa therapy typically quickly results in noticeable&nbsp;improvements (particularly in motor skills). Improvements may be noted within days and in some cases hours following treatment.[787]","dateModified":"2016-07-13T00:00:00","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1310,"questionText":"What is the long-term outlook (prognosis) for people with sepiapterin reductase deficiency?","answerText":"Prognosis depends on disease severity and how quickly treatment can be started.[11293] Children with this condition who are treated with levodopa medications tend to show great improvement in motor skills. The effectiveness of levodopa therapy on cognitive outcome varies. Children often have moderate-to-significant learning disabilities, especially if treatment is delayed.[11293][787]","dateModified":"2016-04-20T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":787,"authors":"Echenne B et al.,","articleTitle":"Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy","bookWebsiteJournalTitle":"Pediatric Neurology","date":"2006 Nov","volume":"35(5)","pages":"308-13","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=17074599","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11293,"authors":"Kamm C","articleTitle":"Dopa-responsive dystonia due to sepiapterin reductase deficiency","bookWebsiteJournalTitle":"Orphanet","date":"November 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1311,"questionText":"Are there any clinical trials enrolling people with sepiapterin reductase deficiency?","answerText":"The National Institutes of Health, through the National Library of Medicine, developed <a href=\"https://clinicaltrials.gov/\" target=\"_blank\">ClinicalTrials.gov</a> to provide patients, family members, and members of the public with current information on clinical research studies. Although no studies involving sepiapterin reductase deficiency  are listed at this time, there is a study, entitled \"Studies of Children with Metabolic and Other Genetic Diseases\", which is evaluating individuals with known or suspected genetic or metabolic diseases. Despite its title, this study is enrolling individuals of all ages. To read about this study, click on the link below. After you click on the study, review its 'eligibility' criteria to determine its appropriateness. <br />\r\n<a href=\"http://www.clinicaltrials.gov/ct/show/NCT00025870?order=1\" target=\"_blank\">http://www.clinicaltrials.gov/ct/show/NCT00025870?order=1</a> <br />\r\n&nbsp;<br />\r\nYou can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling the toll-free number listed below to speak with a specialist, who can help you identify appropriate studies. <br />\r\n<br />\r\nPatient Recruitment and Public Liaison Office (PRPL) <br />\r\nNIH Clinical Center <br />\r\nBethesda, Maryland 20892-2655 <br />\r\nToll-free: 800-411-1222 <br />\r\nFax: 301-480-9793 <br />\r\nEmail: <a href=\"mailto:prpl@mail.cc.nih.gov\">prpl@mail.cc.nih.gov</a> <br />\r\nWeb site: <a href=\"http://clinicalcenter.nih.gov/\" target=\"_blank\">http://clinicalcenter.nih.gov/</a>&nbsp;&nbsp;<br />\r\n<br />\r\nYou can find information about participating in a clinical trials, as well as learn about resources for travel and lodging assistance, through the <a href=\"https://rarediseases.info.nih.gov/research/10/get-involved-in-research\" target=\"_blank\">Get Involved in Research</a> section of our website.","dateModified":"2016-04-20T00:00:00","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":11304,"phenoTypeName":"Abnormality of the nose","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13456,"phenoTypeName":"Bradykinesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11728,"phenoTypeName":"Cognitive impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11416,"phenoTypeName":"Drowsiness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8263,"phenoTypeName":"Hyperhidrosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10649,"phenoTypeName":"Hyperreflexia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10413,"phenoTypeName":"Hypomimic face","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14299,"phenoTypeName":"Limb hypertonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8729,"phenoTypeName":"Motor delay","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9419,"phenoTypeName":"Muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3421,"phenoTypeName":"Muscular hypotonia of the trunk","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14241,"phenoTypeName":"Oculogyric crisis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5615,"phenoTypeName":"Ptosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13451,"phenoTypeName":"Rigidity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11439,"phenoTypeName":"Sleep disturbance","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3494,"phenoTypeName":"Temperature instability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11463,"phenoTypeName":"Cerebral palsy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4082,"phenoTypeName":"Growth delay","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9844,"phenoTypeName":"Microcephaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4080,"phenoTypeName":"Small for gestational age","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6013,"phenoTypeName":"Aggressive behavior","percentRanges":"-"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":8726,"phenoTypeName":"Choreoathetosis","percentRanges":"-"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","percentRanges":"-"},{"phenoTypeId":9421,"phenoTypeName":"Dystonia","percentRanges":"-"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","percentRanges":"-"},{"phenoTypeId":14144,"phenoTypeName":"Hyperactivity","percentRanges":"-"},{"phenoTypeId":6245,"phenoTypeName":"Infantile onset","percentRanges":"-"},{"phenoTypeId":10133,"phenoTypeName":"Oculomotor apraxia","percentRanges":"-"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","percentRanges":"-"},{"phenoTypeId":15605,"phenoTypeName":"Transient hyperphenylalaninemia","percentRanges":"-"},{"phenoTypeId":7381,"phenoTypeName":"Variable expressivity","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Sepiapterin_reductase_deficiency"}